Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis
Authors' conclusion
Our findings indicate a nonlinear dose-response relationship for GLP-1 RAs in managing T2DM. Tirzepatide at a dose of 10 mg/wk is identified as an optimal clinical dose offering a balance between efficacy and safety, contributing to refining T2DM management strategies and potentially enhancing patient outcomes.
Study context
- Population
- Adults with T2D treated with GLP-1 RAs; RCTs published up to October 20, 2024
- Participants
- 17,140 adults62 trials
- Comparison
- GLP-1 RAs at different doses
- Outcome
- Changes in HbA1c, body weight and incidence of adverse events
Methodological detailsmodel-based network meta-analysis, random-effects Bayesian approach, PRISMA, Data extraction by 2 independent researchers
- Model-based network meta-analysis
- Random-effects Bayesian approach
- PRISMA
- Data extraction by 2 independent researchers
Pooled result
As reported in the abstract
Tirzepatide 10 mg/wk: HbA1c reduction
−1.76%
95% CrI −2.10 to −1.41
Tirzepatide 10 mg/wk: body weight reduction
−8.63 kg
95% CrI −9.84 to −7.39
Safety
- Tirzepatide 10 mg/wk: no significant increase in adverse events
Original publication
Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis. Endocr Pract. Published 3 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →